Agnico Eagle Mines Ltd (NYSE:AEM) announced that it had reached a deal with Osisko Mining Corporation and Yamana Gold Inc. to buy the former’s assets for $3.6 billion to curtail a takeover bid by another competitor. Agnico Eagle Mines Ltd (USA)(NYSE:AEM) shares after opening at $29.99 moved to $30.23 on last trade day and at the end of the day closed at $27.88. Company price to sales ratio in past twelve months was calculated as 2.96 and price to cash ratio as 22.50. Agnico Eagle Mines Ltd (USA)(NYSE:AEM) showed a negative weekly performance of -1. 21%.
XG Technology, Inc. (NASDAQ: XGTI) a developer of a portfolio of wireless communications technologies, including cognitive radio networks, announced the pricing of an underwritten public offering of 5,265,000 shares of common stock at a public offering price of $1.90 per share. The Company expects to receive approximately $10,000,000 in gross proceeds, before underwriting discounts and commissions and offering expenses payable by the Company. XG Technology Inc (NASDAQ:XGTI) shares fell -14.29% in last trading session and ended the day on $1.86. XG Technology Inc (NASDAQ:XGTI) yearly performance is 675.00%.
Zion Oil & Gas, Inc. (NASDAQ:ZN) announced that it has extended the expiration date for the Unit program under its Dividend Reinvestment and Common Stock Purchase Plan (“DSPP” or the “Plan”) to Monday June 30, 2014. Units may be purchased under the DSPP at any time prior to 5:00 p.m. Eastern Daylight time on June 30, 2014.Zion Oil & Gas, Inc. (NASDAQ:ZN) shares moved down -7.84% in last trading session and was closed at $2.35, while trading in range of $ 2.30 – 2.61. Zion Oil & Gas, Inc. (NASDAQ:ZN) year to date (YTD) performance is 66.67%.
Ultragenyx Pharmaceutical Inc (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, reported its financial results and business highlights for the fourth quarter and year ended December 31, 2013.”Ultragenyx completed a landmark year in 2013, during which we achieved multiple milestones in our vision to build a next generation rare disease company,” said Emil D. Kakkis, Ph.D., M.D., Chief Executive Officer and President of Ultragenyx. “We have expanded our pipeline to five clinical programs in Phase 1/2 or Phase 2 studies, and with the completion of our initial public offering in early 2014, we believe we are well-positioned to advance multiple programs in parallel to address the significant unmet medical needs of these patients.”Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) weekly performance is -23.10%. On last trading day company shares ended up $45.22. Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) distance from 50-day simple moving average (SMA50) is -13.71%. Analysts mean target price for the company is $77.33.